Modified immunotherapy for alopecia areata

Yoshimasu, Takashi; Furukawa, Fukumi

doi:10.1016/j.autrev.2016.02.021

Cited by 22 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7,8 However, prevalence can vary between 0.1 and 6.9% depending on the population studied. 9 In the United States, AA affects 0.7 to 3% of its population.…”

Section: Epidemiologymentioning

confidence: 99%

“…However, British and Japanese treatment guidelines for AA have suggested topical immunotherapy (dinitrochlorobenzene, diphenylcyclopropenone o el squaric acid dibutylester) as one of the most effective options, 7,8 although intralesional, topical or systemic corticosteroids (fluocinolone acetonide, triamcinolone acetonide, dexamethasone, clobetasol propionate and methylprednisolone), are used in patients with AA. 10,14 Other treatment options include anthralin, azathioprine, 10 cyclosporine, methotrexate, sulfasalazine, minoxidil, 21 adalimumab, 29 tofacitinib and ruxolitinib.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Alopecia Areata. Current situation and perspectives

et al. 2017

View full text Add to dashboard Cite

Alopecia areata (AA) is a dermatological disease characterized by non-scarring hair loss of the scalp and/or body, with an unpredictable and variable evolution in the patients in which, despite multidisciplinary efforts, its etiology is not entirely known, although some evidence suggests that environmental, immunological and genetic factors could be generating the disease. The aim of this review is to provide an updated panorama of the clinical characteristics, diagnosis and treatment of AA, to analyze the mechanisms that could participate in its etiology, as well as to review some of the most important genetic variants that could confer susceptibility to the development of this disease.

show abstract

“…7,8 However, prevalence can vary between 0.1 and 6.9% depending on the population studied. 9 In the United States, AA affects 0.7 to 3% of its population.…”

Section: Epidemiologymentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Alopecia Areata. Current situation and perspectives

et al. 2017

View full text Add to dashboard Cite

show abstract

“…7,8 Sin embargo, la prevalencia puede variar entre 0,1% y 6,9% dependiendo de la población estudiada. 9 En Estados Unidos (EE.…”

Section: Epidemiologíaunclassified

“…Sin embargo, las guías de tratamientos para AA británica y japonesa han sugerido la inmunoterapia tópica (dinitroclorobenceno, difenilciclopropenona o el ácido escuárico dibutilester) como una de las opciones más efectivas, 7,8 aunque también los corticoesteroides intralesionales, tópicos o sistémicos (acetónido de fluocinolona, triamcinolona acetonida, dexametasona, propionato de clobetasol, metilprednisolona y otros) son empleados en los pacientes con AA. 10,14 Otras opciones de tratamiento incluyen la antralina, azatioprina, 10 ciclosporina, m e t o t r e x a t o , s u l f a s a l a z i n a , m i n o x i d i l , 21 adalimumab, 29 tofacitinib y ruxolitinib.…”

unclassified

Alopecia areata. Actualidad y perspectivas

et al. 2017

View full text Add to dashboard Cite

RESUMENLa alopecia areata es un padecimiento dermatológico caracterizado por la pérdida de pelo no cicatricial del cuero cabelludo y/o del cuerpo, con una evolución impredecible y variable en los pacientes. A pesar de esfuerzos multidisciplinarios, su etiología sigue sin conocerse con exactitud, aunque algunas evidencias sugieren que factores ambientales, inmunológicos y genéticos podrían estar originando la enfermedad. El objetivo de esta revisión consiste en dar un panorama actual de las características clínicas, diagnóstico y tratamiento de la alopecia areata, analizar los mecanismos que podrían participar en su etiología, así como revisar algunas de las variantes génicas más importantes, que podrían conferir susceptibilidad al desarrollo de la enfermedad. Palabras clave: alopecia areata, genes, susceptibilidad.

show abstract

“…On the other hand, 'modified' immunotherapy for AA such as combination therapy with contact immunotherapy and steroid pulse and contact immunotherapy without sensitization at a starting point are also reported, currently. 7 We experienced promoted hair regrowth in refractory multiple AA after the combination therapy of contact immunotherapy using diphenylcyclopropenone (DPCP) with oral bepotastine besilate, oral hydroxyzine hydrochloride and intermitted application of topical corticosteroid.…”

Section: Introductionmentioning

confidence: 99%

Successful Treatment of Multiple Alopecia Areata With Contact Immunotherapy: Supportive Usage of Oral Antihistamine and Topical Corticosteroid

Kaga¹,

Ikeda²

2017

Dermatol Open J

View full text Add to dashboard Cite

Contact immunotherapy using diphenylcyclopropenone (DPCP) is a commonly used first-line therapeutic technique for patients with alopecia areata (AA). We present here a successful immunotherapy for AA female case with atopic diathesis, using oral antihistamine and topical corticosteroid supportively on DPCP. Courses of clinical and laboratory findings suggested that indirect effect to allergic inflammation by antihistamine drugs contributed to AA regression in our case.

show abstract

Modified immunotherapy for alopecia areata

Cited by 22 publications

References 30 publications

Alopecia Areata. Current situation and perspectives

Alopecia Areata. Current situation and perspectives

Alopecia areata. Actualidad y perspectivas

Successful Treatment of Multiple Alopecia Areata With Contact Immunotherapy: Supportive Usage of Oral Antihistamine and Topical Corticosteroid

Contact Info

Product

Resources

About